Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity

7 May 2021

Abstract excerpt

Homologous recombination repair deficiency (HRD) can be observed in virtually all cancer types. Although HRD sensitizes tumors to DNA-damaging chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors, all patients ultimately develop resistance to these therapies. Therefore, it is necessary to identify therapeutic regimens with a more durable efficacy. HRD tumors have been suggested to be more immunogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to PARP inhibition in cancer therapy
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34067105
DOI: 10.3390/cancers13092249

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homologous Recombination Repair Deficiency and Implications for Tumor ImmunogenicityPMID 34067105Read ↗

The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancersSemantic proximity Read ↗

Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer typesSemantic proximity Read ↗

Homologous Recombination Deficiency as a Novel Therapeutic Target in Various Solid TumorsSemantic proximity Read ↗

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read ↗

Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.Semantic proximity Read ↗

Therapeutic targeting and patient selection for cancers with homologous recombination defects.Semantic proximity Read ↗

Homologous recombination repair deficiency (HRD): From biology to clinical exploitationSemantic proximity Read ↗

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision OncologySemantic proximity Read ↗

DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errorsSemantic proximity Read ↗

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical ApplicationsSemantic proximity Read ↗

Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency.Semantic proximity Read ↗

Multiomics analysis of homologous recombination deficiency across cancer types.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.